BioMarin (BMRN) Q1 2026 earnings review
M&A Boosts Top-Line Guidance, But Organic Margins Suffer
BioMarin's Q1 2026 results present a sharp divergence between organic operational struggles and aggressive M&A-driven forecasting. Total Revenue decelerated to just 3% YoY growth ($766M), while Non-GAAP EPS fell 33% to $0.76. Margins were significantly compressed by a $31M charge from a failed NAGLAZYME manufacturing campaign and integration costs for the Amicus Therapeutics acquisition. VOXZOGO, the supposed growth engine, flatlined sequentially and grew only 3% YoY due to Q4 order pull-forwards, despite management claiming 20%+ patient volume growth. The market's focus, however, will shift to the newly raised FY26 guidance—boosting revenue expectations by $500M to ~$3.87B (20% YoY growth) as Amicus's commercial assets (GALAFOLD, POMBILITI) join the portfolio in Q2.
🐂 Bull Case
The addition of Amicus Therapeutics completely changes the FY26 trajectory. Full-year revenue guidance was raised to imply 20% YoY growth, instantly diversifying the portfolio with high-margin Fabry and Pompe disease assets.
BMN 333 (long-acting CNP) entered its registration-enabling Phase 2/3 study for achondroplasia. If it demonstrates superiority over VOXZOGO as planned, it secures BioMarin's dominance in the space well into the 2030s.
🐻 Bear Case
GAAP Operating Margin collapsed from 30.0% in 25Q1 to 16.9% in 26Q1. An unforced $31M manufacturing error (unsuccessful NAGLAZYME process qualification) highlights poor execution that directly punishes the bottom line.
Despite management citing 20%+ growth in children treated, VOXZOGO reported revenue grew a paltry 3% YoY to $220M. Heavy reliance on lumpy government orders makes quarter-to-quarter performance highly erratic.
⚖️ Verdict: ⚪
Neutral. The inorganic top-line acceleration from Amicus is highly attractive, but it papers over Q1's messy organic execution. A $31M manufacturing blunder and stalled sequential growth in key product lines demand caution.
Key Themes
Amicus Acquisition Transforms 2026 Outlook
With the Amicus integration commencing in April 2026, BioMarin is effectively absorbing a massive new commercial revenue stream. The immediate impact is a $500M raise to FY26 Revenue guidance (now $3.825B–$3.925B). The strategy is to plug GALAFOLD (Fabry) and POMBILITI + OPFOLDA (Pompe) directly into BioMarin's established global rare disease infrastructure to accelerate ex-U.S. penetration.
Manufacturing Error Punishes Margins
Cost of Sales surged 28% YoY to $195M, heavily driven by a $31M charge for an unsuccessful process qualification campaign designed to expand NAGLAZYME manufacturing. This single blunder shaved approximately $0.12 off EPS for the quarter. Combined with Amicus pre-close costs, GAAP Operating Margin essentially halved YoY from 30.0% to 16.9%.
VOXZOGO Optical Deceleration
VOXZOGO revenue decelerated violently to 3% YoY growth ($220M), breaking a streak of rapid expansion (it grew 40% YoY in the same quarter last year). Management claims the underlying metric—children treated—grew over 20%. The disconnect is entirely blamed on the timing of large Q4 2025 government orders outside the U.S., highlighting severe revenue lumpiness.
PALYNZIQ Unexpectedly Reverses to Contraction
PALYNZIQ reversed from being a consistent >20% YoY growth engine throughout 2025 to a 3% YoY decline in 26Q1 ($90M vs $93M). This contraction occurred despite the FDA label expansion to adolescents (12+) in February. If the label expansion cannot offset adult attrition or pricing pressures, a core pillar of the Enzyme Therapies base is at risk.
Skeletal Pipeline Advancing Rapidly
Innovation continues on schedule. The company submitted its sNDA for full approval of VOXZOGO in achondroplasia, with acceptance expected in Q3 2026. More importantly, the first patient was dosed in the Phase 2/3 study for BMN 333 (long-acting CNP), explicitly designed to establish superiority over VOXZOGO. Topline Phase 3 data for VOXZOGO in hypochondroplasia is also due in Q2 2026, which could unlock a new 14,000-patient market.
Other KPIs
Stable. Grew 6% YoY, largely carrying the quarter's top-line. Driven by steady growth in mature products like VIMIZIM (+12%) and NAGLAZYME (+14%), counterbalancing the unexpected weakness in PALYNZIQ (-3%) and the typical lumpiness of ALDURAZYME (-24%).
Accelerating. An excellent result for Q1, ending the quarter with a massive $3.07 billion in total cash, cash equivalents, and restricted cash (which includes $850M in newly issued debt specifically ring-fenced for closing the Amicus transaction). This strong liquidity supports both the acquisition and aggressive R&D funding.
Guidance
Accelerating. Guidance was massively raised from the prior $3.325B-$3.425B range to reflect the Amicus Therapeutics integration. At the midpoint ($3.875B), this implies a robust 21% YoY growth rate over FY25's $3.2B, completely resetting the top-line trajectory.
Decelerating relative to prior guidance, but accelerating YoY. The range was nudged down from $4.95-$5.15 strictly due to the Amicus acquisition being 'slightly dilutive' to 2026 EPS (interest expense and integration costs). Still, the $4.95 midpoint implies aggressive 57% YoY growth compared to FY25's $3.15.
Stable. Unchanged from prior guidance. Reaching the midpoint implies ~8% YoY growth over FY25's $927M, which means VOXZOGO must accelerate sequentially through the rest of the year after a flat Q1 to hit this target.
Key Questions
PALYNZIQ Disconnect
PALYNZIQ revenue contracted 3% YoY despite the recent label expansion to adolescents. Is this purely an inventory dynamic, or are we seeing pushback on price/compliance issues in the adult population?
NAGLAZYME Manufacturing Resolution
You recorded a $31M charge for an unsuccessful NAGLAZYME process qualification. What specifically failed, has the root cause been fully mitigated, and is there any risk to commercial supply or further write-downs in 2026?
Amicus Integration and Synergies
With Amicus being slightly dilutive to FY26 EPS, what is the specific timeline for the transaction to turn accretive, and how quickly can BioMarin's global infrastructure expand GALAFOLD and POMBILITI outside the U.S.?